Abstract
This commentary discusses the findings of Agalliu and colleagues, who performed a population-based, case–control study on the association between statin drugs and prostate cancer risk. Consistent with recent studies, statins were not associated with overall prostate cancer risk, but users had a possible lower risk of advanced disease. Obese men taking a statin had a higher risk of prostate cancer than those not taking a statin; however, a previously conducted, large, prospective, cohort study did not observe this association. This unexpected finding by Agalliu et al. could be a chance result, or could have arisen because of complex bias. Although statins might favorably affect men's prostate health, evidence is too limited to recommend statin use for the prevention of advanced prostate cancer. Consideration of the harms and benefits when prescribing a statin for vascular indications, including in obese men, should not presently include prostate cancer risk.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Agalliu I et al. (2008) Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 168: 250–260
Platz EA (2007) Epidemiologic musing on statin drugs in the prevention of advanced prostate cancer. Cancer Epidemiol Biomarkers Prev 16: 2175–2180
Friedman GD et al. (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17: 27–36
Boudreau DM et al. (2008) Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 19: 767–774
Kuoppala J et al. (2008) Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 44: 2122–2132
Ridker PM et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207
Platz EA et al. (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98: 1819–1825
Acknowledgements
Dr Platz is supported in part by Public Health Service research grant P50 CA58236 from the National Cancer Institute, NIH, Department of Health and Human Services. The content is solely the responsibility of the author and does not necessarily represent the official view of the National Cancer Institute or the NIH.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Platz, E. Does statin use affect the risk of developing prostate cancer?. Nat Rev Urol 6, 70–71 (2009). https://doi.org/10.1038/ncpuro1295
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro1295
This article is cited by
-
Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis
Clinical & Experimental Metastasis (2015)